Status:
COMPLETED
Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
Lead Sponsor:
AB Science
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.
Eligibility Criteria
Inclusion
- Patients aged 18 to 60 years, from both sex, and suffering from multiple sclerosis either primary progressive or secondary progressive without relapse within 2 years before inclusion.
- Patients with EDSS score in the range of 2 to 6.5, inclusive
- EDSS progression ≥ 1 point within 2 years before inclusion
Exclusion
- Disease other than MS responsible for clinical signs and/or MRI lesions
- Secondary progressive MS with relapse in the 2 years before inclusion
- Treatment with interferon or glatiramer acetate within four weeks prior to treatment allocation
- Treatment with oral or systemic corticosteroids or ACTH within four weeks prior to treatment allocation.
- Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01450488
Start Date
June 1 2005
End Date
January 1 2010
Last Update
December 11 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.